MacroGenics, Inc. (MGNX)

Market Cap	256.80M
Revenue (ttm)	43.36M
Net Income (ttm)	-23.24M
Shares Out	62.63M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	887,192
Open	4.280
Previous Close	4.300
Day's Range	4.030 - 4.290
52-Week Range	3.140 - 21.880
Beta	2.00
Analysts	Buy
Price Target	12.44 (+203.42%)
Earnings Date	Aug 7, 2024

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibod...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2013
• Employees: 339
• Stock Exchange: NASDAQ
• Ticker Symbol: MGNX

Financial Performance

In 2023, MacroGenics's revenue was $58.75 million, a decrease of -61.33% compared to the previous year's $151.94 million. Losses were -$9.06 million, -92.44% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price forecast is $12.44, which is an increase of 203.42% from the latest price.

Price Target

$12.44

(203.42% upside)

Analyst Consensus: Buy